Navigation Links
Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
Date:12/23/2009

IRVINE, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, today announced that its management is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 11, 2010, at 2:00 p.m. Pacific Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET® provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI® and acoustic respiration rate (RRa), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.


    Masimo Corporation
    Investor Contact:                         Media Contact:
    Sheree Aronson                            Dana Banks
    Vice President, Investor Relations        Manager, Public Relations
    Masimo Corporation                        Masimo Corporation
    (949) 297-7043                            (949) 297-7348
    saronson@masimo.com                       dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo Corporation


'/>"/>
SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Clinical Study Finds Masimo Perfusion Index (PI) Predicts Low Systemic Blood Flow in Preterm Infants
2. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
3. Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress
4. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
5. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
6. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
7. Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
8. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
9. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... After the recent election cycle, it ... cannabis both for medical and recreational purposes are shifting. The ... the use of cannabis, but the focus is coming from ... Research, the North American legal cannabis market posted $6.7 billion ... The research projects sales will grow at a compound annual ...
(Date:1/18/2017)... National Regulatory Authority Chinese Food and Drug Administration ... Flanders Institute Food and Drug Administration FORT ... Alliance Glaxo Smith Klein GlaxoWellcome ... Japan Immune Targeting Systems Indian ... of oxford Johnson & Johnson Krka Pharmaceuticals ...
(Date:1/17/2017)... , Jan. 17, 2017 Secretary of ... Alcohol Programs Secretary Gary Tennis are warning ... following two recent overdose deaths from the drug in ... "Carfentanil is intended to sedate large animals and is ... anyone who comes into contact with it," Secretary Murphy ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... In the ... Activewear is a stand-out company for several differences from other mainstream brands. ... on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows ...
(Date:1/17/2017)... ... 17, 2017 , ... Healthful Balance announces the national release ... operated by Ed Stroup, was created to offer the highest quality vitamins and ... customer service. Healthful Balance products can be purchased online through their website, or ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... enthusiasts at the National Association of Music Merchants (NAMM) winter trade show, Booth ... 2017. , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear ...
(Date:1/17/2017)... ... , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is ... Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror ... Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New ... eye care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment ... Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of ...
Breaking Medicine News(10 mins):